WASHINGTON — Last week, The Hill hosted an event titled, “Prescription for Change: Improving Competition to Lower Drug Prices.” During the event, lawmakers and a panel of drug pricing and economic experts discussed the importance of promoting competition as the most effective way to lower prescription drug costs. Panelists also highlighted and explained the root cause of high
WASHINGTON — The Pharmaceutical Care Management Association, PCMA, applauds Senators Maggie Hassan (D, N.H.) and Mike Braun (R, Ind.) for recently reintroducing legislation, the Prescription Drug Competition Act, which aims to encourage greater competition in the prescription drug market that is critical to helping lower costs. The bill targets potential abuses of Risk Evaluation and
WASHINGTON — The Pharmaceutical Care Management Association (PCMA) released a new policy platform, “Unlocking an Affordable Future,” designed to provide policymakers a roadmap to prioritize patients with public policy solutions that promote competition in the prescription drug market, lower costs, and support better health outcomes. The “Unlocking an Affordable Future” platform calls on policymakers and
WASHINGTON — The Pharmaceutical Care Management Association (PCMA) is pleased to announce that Amy Bricker, president of Express Scripts, has assumed the role of chair of the PCMA board of directors. Prior to today’s announcement, Bricker held the position of vice-chair. Bricker succeeds William Fleming president, pharmacy solutions and chief corporate affairs officer of Humana
WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott issued the following statement on the Biden Administration’s announcement to curb drug manufacturer patent abuses. “We applaud the Biden Administration for taking real action to reduce prescription drug costs. Drug manufacturer pricing strategies that include patent thickets on certain brand drugs unfairly protect
WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott issued the following statement on today’s vote in the Commerce Committee on “The Pharmacy Benefit Manager Transparency Act of 2022″ – legislation the industry deems anti-competitive and harmful to patients, while providing the Federal Trade Commission (FTC) an egregious and unprecedented expansion of
WASHINGTON — The Pharmaceutical Care Management Association (PCMA) announced that Katie Payne has been appointed Senior Vice President of Strategic Communications. In her role, Ms. Payne will be responsible for leading PCMA’s communications function and will oversee the development of the association’s communications and public affairs strategy aimed at increasing understanding of the ways pharmacy
WASHINGTON — The Pharmaceutical Care Management Association (PCMA) issued the following statement on a new Milliman report on insulin coverage in Medicare Part D. A new report conducted by the actuarial firm Milliman, “A Summary of Insulin Coverage in Medicare Part D,” shows that insulin products are widely covered on Medicare Part D formularies. “We support
WASHINGTON — The Pharmaceutical Care Management Association (PCMA) released the following statement on S. 1388, the “Prescription Drug Pricing for the People Act.” PCMA, the trade association for America’s pharmacy benefit managers (PBMs), today endorsed S. 1388, the “Prescription Drug Pricing for the People Act,” sponsored by Sen. Charles Grassley (R, Iowa). The bipartisan legislation
WASHINGTON — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott today issued the following statement supporting the policy of one-stop COVID-19 testing and treatment at pharmacies and calling on the Biden Administration to expand the scope of its recently-announced “Test to Treat” program: “We applaud the Biden administration on its efforts to increase
WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott released the following statement on today’s Senate Finance Committee hearing, “Prescription Drug Price Inflation: An Urgent Need to Lower Drug Prices in Medicare.” “PCMA commends the Senate Finance Committee for holding this important hearing on drug price inflation. We share the committee’s goal
WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott today issued the following statement on H.R. 7008, the Pre-approval Information Exchange (PIE) Act: “The introduction of the PIE Act is an important step forward in establishing a value-based health care system. We applaud Rep. Brett Guthrie (R-KY) for his longtime focus on
WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott issued the following statement on the 2023 Medicare Part D proposed rule from the Centers for Medicare & Medicaid Services (CMS): “We are currently reviewing the proposed rule. However, previous point-of-sale proposals in Medicare have not advanced because they would significantly increase Medicare
WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott issued the following statement on Congress’ passage of the Bipartisan Infrastructure Package: “We applaud Congress for passing the infrastructure legislation, which, when signed into law, will enact a three-year delay of the Medicare Part D rebate rule. There is no question that the rebate
